Cemil Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 0.12 M
as on 10-12-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.00 M
as on 10-12-2024
- Revenue -77.26%
(FY 2021)
- Profit 34.89%
(FY 2021)
- Ebitda 44.38%
(FY 2021)
- Net Worth -71.03%
(FY 2021)
- Total Assets 4.28%
(FY 2021)
About Cemil Biosciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹7.00 M.
Sherry Kuruvila and Jerry Kuruvilla serve as directors at the Company.
- CIN/LLPIN
U24100KA2019PTC120414
- Company No.
120414
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cemil Biosciences Private Limited offer?
Cemil Biosciences Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Bio Chemicals, Food Packaging Materials & Supplies, Edible Packaging Tray, Plastic & Glass Labware, Laboratory Glassware, Industrial Chemicals & Supplies, Agro Chemicals, Laboratory Plates, Biocides.
Who are the key members and board of directors at Cemil Biosciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jerry Kuruvilla  | Director | 15-Jan-2019 | Current |
| Sherry Kuruvila | Director | 15-Jan-2019 | Current |
Financial Performance of Cemil Biosciences.
Cemil Biosciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 77.26% decrease. The company also saw a substantial improvement in profitability, with a 34.89% increase in profit. The company's net worth observed a substantial decline by a decrease of 71.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cemil Biosciences?
In 2021, Cemil Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hoteltek Beverages Private LimitedActive 16 years 9 monthsSherry Kuruvila and Jerry Kuruvilla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 23 Aug 2024 | ₹7.00 M | Open |
How Many Employees Work at Cemil Biosciences?
Unlock and access historical data on people associated with Cemil Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cemil Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cemil Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
